NexgenRx Inc.
NXG.V
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.05M | 2.93M | 3.02M | 2.72M | 2.88M |
| Total Other Revenue | 300.50K | 214.70K | 146.90K | 97.10K | 105.10K |
| Total Revenue | 3.35M | 3.14M | 3.17M | 2.81M | 2.98M |
| Cost of Revenue | 556.00K | 567.70K | 645.70K | 405.20K | 662.10K |
| Gross Profit | 2.80M | 2.57M | 2.53M | 2.41M | 2.32M |
| SG&A Expenses | 2.13M | 2.10M | 1.92M | 1.85M | 1.97M |
| Depreciation & Amortization | 227.50K | 233.40K | 218.80K | 225.60K | 227.10K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.91M | 2.90M | 2.79M | 2.48M | 2.86M |
| Operating Income | 442.20K | 245.00K | 383.10K | 332.50K | 123.00K |
| Income Before Tax | 411.60K | 239.00K | 351.40K | 323.70K | 92.70K |
| Income Tax Expenses | -16.60K | -16.50K | -15.90K | 343.40K | -16.80K |
| Earnings from Continuing Operations | 428.20K | 255.50K | 367.30K | -19.70K | 109.40K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 428.20K | 255.50K | 367.30K | -19.70K | 109.40K |
| EBIT | 442.20K | 245.00K | 383.10K | 332.50K | 123.00K |
| EBITDA | 669.70K | 478.40K | 580.10K | 369.70K | 350.10K |
| EPS Basic | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 71.12M | 71.12M | 71.12M | 70.47M | 71.08M |
| Average Diluted Shares Outstanding | 84.25M | 76.92M | 76.72M | 70.47M | 71.08M |
| Dividend Per Share | 0.00 | 0.00 | -- | 0.00 | 0.00 |
| Payout Ratio | 65.89% | 109.92% | 6.26% | -370.20% | 22.11% |